Science and Self: Monitoring Response to MS Treatment with Biomarkers and Patient-Reported Outcomes

Release: 12/15/21

Expiration: 12/15/22

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.

This activity is supported by independent grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credits
  • Nurses — 1.0 contact hours of continuing nursing education (1.0 in the area of pharmacology)
  • Pharmacists — maximum of 1.0 contact hours of continuing pharmacy education credit

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of neurologists, nurse practitioners, PAs, nursing professionals, pharmacists, and other members of the healthcare team essential to the care of patients living with MS.

Program Overview

This enduring activity is designed to review the role of biomarkers and patient-reported outcomes (PROs) in the management of people living with multiple sclerosis (MS).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current research and emerging data on biomarkers as potential tool for measuring treatment response in MS patients
  • Identify patient-reported outcomes and tools that can be incorporated into the clinical setting to measure response to MS treatment


Edward J. Fox, MD, PhD

Director, MS Clinic of Central Texas
Central Texas Neurology Consultants
Clinical Associate Professor, University of Texas Dell Medical School


About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts